Cargando…

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

OBJECTIVES: To evaluate treatment with the peptide-based agent, Lupuzor, in a double-blind, randomised, placebo-controlled study of patients with systemic lupus erythematosus. METHODS: Patients who met ≥4 of the American College of Rheumatology criteria, had a score of ≥6 on the Systemic Lupus Eryth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zimmer, Robert, Scherbarth, Hugo R, Rillo, Oscar Luis, Gomez-Reino, Juan Jesus, Muller, Sylviane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2013
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812851/ https://www.ncbi.nlm.nih.gov/pubmed/23172751 http://dx.doi.org/10.1136/annrheumdis-2012-202460

Ejemplares similares

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
por: Wallace, Daniel J, et al.
Publicado: (2014)

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
por: Khamashta, Munther, et al.
Publicado: (2016)

Cohort profile: systemic lupus erythematosus in Sweden: the Swedish Lupus Linkage (SLINK) cohort
por: Arkema, Elizabeth V, et al.
Publicado: (2015)

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
por: Morand, Eric F, et al.
Publicado: (2018)

A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
por: Zhang, Fengchun, et al.
Publicado: (2018)

Real-world incidence and prevalence of systemic lupus erythematosus in Alberta, Canada
por: Fatoye, Francis, et al.
Publicado: (2018)

Coping with systemic lupus erythematosus in patients’ words
por: Cornet, Alain, et al.
Publicado: (2022)

Clinical and histopathological features of myositis in systemic lupus erythematosus
por: Tiniakou, Eleni, et al.
Publicado: (2022)

Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects
por: Monneaux, Fanny, et al.
Publicado: (2009)

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Maternal Deworming Research Study (MADRES) protocol: a double-blind, placebo-controlled randomised trial to determine the effectiveness of deworming in the immediate postpartum period
por: Mofid, Layla S, et al.
Publicado: (2015)

Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis
por: Murimi-Worstell, Irene B, et al.
Publicado: (2020)

Causes and outcome of hospitalisations in Tunisian patients with systemic lupus erythematosus
por: Jallouli, M, et al.
Publicado: (2014)

Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)

Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations
por: Meyer, Aurore, et al.
Publicado: (2020)

Development of a systemic lupus erythematosus cardiovascular risk equation
por: Petri, Michelle A, et al.
Publicado: (2019)

Association of patient copayment and medication adherence in systemic lupus erythematosus
por: Lomanto Silva, Raisa, et al.
Publicado: (2023)

Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty‐Four–Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Arm, Phase IIb Study
por: Merrill, Joan T., et al.
Publicado: (2018)

P140 Peptide Leads to Clearance of Autoreactive Lymphocytes and Normalizes Immune Response in Lupus-Prone Mice
por: Schall, Nicolas, et al.
Publicado: (2022)

Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis
por: Kandala, Ngianga-Bakwin, et al.
Publicado: (2013)

Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study
por: Jiang, Xiaofeng, et al.
Publicado: (2023)

Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review
por: Strand, Vibeke, et al.
Publicado: (2020)

Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials
por: Xie, Wenhui, et al.
Publicado: (2021)

Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus
por: Carli, L, et al.
Publicado: (2016)

Complement levels and risk of organ involvement in patients with systemic lupus erythematosus
por: Gandino, Ignacio Javier, et al.
Publicado: (2017)

Serum uric acid is associated with damage in patients with systemic lupus erythematosus
por: Elera-Fitzcarrald, Claudia, et al.
Publicado: (2020)

Living with systemic lupus erythematosus in 2020: a European patient survey
por: Cornet, Alain, et al.
Publicado: (2021)

Attribution of cause of end-stage renal disease among patients with systemic lupus erythematosus: the Georgia Lupus Registry
por: Plantinga, Laura C, et al.
Publicado: (2016)

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
por: Giannakou, Ioanna, et al.
Publicado: (2018)

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
por: He, Jing, et al.
Publicado: (2020)

Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study
por: Furie, Richard A, et al.
Publicado: (2022)

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence
por: Osmani, Zgjim, et al.
Publicado: (2021)

Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus
por: Zhu, Lisa, et al.
Publicado: (2022)

Fc γ R IIB gene polymorphisms in Indian systemic lupus erythematosus (SLE) patients
por: Pradhan, Vandana, et al.
Publicado: (2011)

Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort
por: Al Sawah, Sarah, et al.
Publicado: (2015)

Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s
por: Albrecht, Katinka, et al.
Publicado: (2014)

Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival
por: Kazzaz, Nayef M, et al.
Publicado: (2015)

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures
por: Thanou, Aikaterini, et al.
Publicado: (2019)

Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
por: Sivakumaran, Jagan, et al.
Publicado: (2021)

Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study
por: Schlencker, Aurelien, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4qgve09rjv42l8lo6kam6hvmhs